X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs UNICHEM LAB - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA UNICHEM LAB AUROBINDO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 15.7 -66.6 - View Chart
P/BV x 3.9 0.7 528.4% View Chart
Dividend Yield % 0.4 2.3 17.5%  

Financials

 AUROBINDO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
UNICHEM LAB
Mar-18
AUROBINDO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs895382 234.3%   
Low Rs622234 265.7%   
Sales per share (Unadj.) Rs254.6116.3 218.9%  
Earnings per share (Unadj.) Rs39.3-18.9 -207.6%  
Cash flow per share (Unadj.) Rs46.6-11.7 -396.7%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.31.6 20.3%  
Book value per share (Unadj.) Rs160.0381.0 42.0%  
Shares outstanding (eoy) m585.8870.34 832.9%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x3.02.6 112.5%   
Avg P/E ratio x19.3-16.3 -118.6%  
P/CF ratio (eoy) x16.3-26.2 -62.1%  
Price / Book Value ratio x4.70.8 586.5%  
Dividend payout %6.4-26.4 -24.1%   
Avg Mkt Cap Rs m444,39021,668 2,050.9%   
No. of employees `00014.02.3 613.2%   
Total wages/salary Rs m17,6782,006 881.1%   
Avg. sales/employee Rs Th10,667.83,587.8 297.3%   
Avg. wages/employee Rs Th1,264.3880.0 143.7%   
Avg. net profit/employee Rs Th1,645.8-583.7 -281.9%   
INCOME DATA
Net Sales Rs m149,1578,180 1,823.4%  
Other income Rs m1,159610 190.0%   
Total revenues Rs m150,3168,790 1,710.0%   
Gross profit Rs m34,343-1,320 -2,601.3%  
Depreciation Rs m4,276505 846.6%   
Interest Rs m66780 833.0%   
Profit before tax Rs m30,558-1,295 -2,359.2%   
Minority Interest Rs m500-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,59733 22,730.4%   
Profit after tax Rs m23,012-1,331 -1,729.0%  
Gross profit margin %23.0-16.1 -142.7%  
Effective tax rate %24.9-2.6 -963.5%   
Net profit margin %15.4-16.3 -94.8%  
BALANCE SHEET DATA
Current assets Rs m92,06223,318 394.8%   
Current liabilities Rs m66,2234,635 1,428.7%   
Net working cap to sales %17.3228.4 7.6%  
Current ratio x1.45.0 27.6%  
Inventory Days Days106122 87.0%  
Debtors Days Days68121 55.7%  
Net fixed assets Rs m62,9198,163 770.8%   
Share capital Rs m586141 416.4%   
"Free" reserves Rs m93,13326,660 349.3%   
Net worth Rs m93,71926,801 349.7%   
Long term debt Rs m1,8143 54,969.7%   
Total assets Rs m162,49431,890 509.6%  
Interest coverage x46.8-15.2 -308.5%   
Debt to equity ratio x00 15,719.7%  
Sales to assets ratio x0.90.3 357.8%   
Return on assets %14.6-3.9 -371.5%  
Return on equity %24.6-5.0 -494.4%  
Return on capital %32.7-4.5 -720.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,8384,356 1,740.8%   
Fx outflow Rs m30,2240-   
Net fx Rs m45,6134,356 1,047.0%   
CASH FLOW
From Operations Rs m32,786-1,123 -2,918.4%  
From Investments Rs m-17,87016,487 -108.4%  
From Financial Activity Rs m-19,153-8,811 217.4%  
Net Cashflow Rs m-4,2396,552 -64.7%  

Share Holding

Indian Promoters % 54.1 50.1 108.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 15.1 52.6%  
FIIs % 27.7 3.0 923.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 31.7 32.2%  
Shareholders   69,601 20,176 345.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS